Charles River Laboratories management check
CRL · Health Care · Life Sciences Tools & Services · CEO Birgit Girshick (since the last proxy; previously Mr. Foster)
Filings as of
Closest peers in Life Sciences Tools & Services
- 101WATWaters Corporation76
- 108MTDMettler Toledo76
- 151DHRDanaher Corporation72
- 168IQVIQVIA71
- 307TMOThermo Fisher Scientific61
- 375CRLCharles River Laboratories56
- 386AAgilent Technologies55
- 443ILMNIllumina, Inc.47
- 453TECHBio-Techne45
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
016thDetail
$100 invested at the start of fiscal 2021 grew to $81, against $148 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9376thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.86 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- FlagPaid in a loss-making year
What does the CEO cost owners?
$15.4m pay · −$144.3m net income, FY2025
016thDetail
$15.4m of reported pay in fiscal 2025, a year the company lost $144.3m.
- WatchNew CEO since the proxy
Do they own the stock?
Birgit Girshick: 35,485 shares
6 mo: ▲ $3k bought · ▼ $52.1m sold
——Detail
Birgit Girshick filed as Chief Executive Officer after the last proxy (which named Mr. Foster) and holds 35,485 shares. Their pay will be in the next proxy. 6 insiders sold $52.1m in the last six months, against $3k bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −1.9% a year; flagged above +2%
Stock pay 1.8% of revenue
7365thDetail
Diluted shares changed -1.9% a year over the last three fiscal years. Stock-based pay was 1.8% of revenue in the latest year.
- WatchNew CEO: Birgit Girshick
Is leadership stable?
9 filings under 8-K 5.02 in 3 years
CEO: Mr. Foster → Birgit Girshick (new)
7046thDetail
Birgit Girshick has filed as CEO since the last proxy. CEO in the pay table: Mr. Foster. 9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 31, 2026.
Pay tied most to Non- GAAP EPS
Other key measuresRevenueNon-GAAP EPSNon-GAAP Operating Income
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Foster | $15.4m | $24.9m | $3.6m | $81 | $148 | −$144.3m |
| 2024 | — | $13.5m | $3.1m | $3.5m | $74 | $129 | $10.3m |
| 2023 | — | $14.1m | $20.5m | $3.7m | $94 | $126 | $474.6m |
| 2022 | — | $13.4m | $10.7m | $3.3m | $87 | $124 | $486.2m |
| 2021 | — | $13.7m | $41.2m | $4.4m | $147 | $126 | $391.0m |
Insiders and the CEO's stakeSelling
- Chief Executive Officer
- Birgit Girshick
- Shares held
- 35,485
- Latest Form 4
- Aug 19, 2026
6 insiders sold $52.1m in the last six months, against $3k bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- BoughtGlenn ColemanEVP & Chief Financial Officer$3kSep 30, 2026
- SoldJames C FosterDirector · 10b5-1 plan$43.3mOct 22, 2026
- SoldShannon M ParisottoCEVP, Disc & Safety Assessment · 10b5-1 plan$4.0mOct 21, 2026
- SoldBirgit GirshickChief Executive Officer · 10b5-1 plan$1.8mAug 11, 2026
Leadership and governance on file
All 13 filings
- May 11, 2026Leadership change8-K 5.02
- Feb 18, 2026Leadership change8-K 5.02
- Jan 9, 2026Leadership change8-K 5.02
- Sep 19, 2025Leadership change8-K/A 5.02
- Sep 16, 2025Leadership change8-K 5.02
- May 23, 2025Leadership change8-K 5.02
- May 7, 2025Leadership change8-K 5.02
- Jan 24, 2024Leadership change8-K 5.02
- Jan 16, 2024Leadership change8-K 5.02
- Dec 6, 2022Leadership change8-K 5.02
- Mar 28, 2022Leadership change8-K 5.02
- Jan 11, 2022Leadership change8-K 5.02
- Dec 27, 2021Leadership change8-K 5.02
Latest shareholder vote results: May 11, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $583.4m returned to owners in buybacks and dividends, 47% of net income, and $358.1m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.5bn | $4.0bn | $4.1bn | $4.0bn | $4.0bn |
| Net income | $391.0m | $486.2m | $474.6m | $22.2m | −$144.3m |
| Stock-based pay | $71.5m | $73.6m | $72.0m | $69.9m | $71.1m |
| Buybacks | $40.7m | $38.7m | $24.2m | $119.2m | $360.7m |
| Dividends | — | — | — | — | — |
| Diluted shares | 51m | 51m | 51m | 52m | 50m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.